Situation: A 52-year-old woman taking estrogen-containing hormone therapy is admitted to the intensive care unit (ICU) 3 days after a 14-hour flight. Computed tomography pulmonary angiography confirms pulmonary embolism (PE). She weighs 75 kg and has no history of bleeding, stroke, recent surgery, or head injury. On day 7 of heparin, her platelet count is 98,000/mm³; it was 240,000/mm³ on admission. The physician stops all heparin, including line flushes, and starts a non-heparin anticoagulant rather than simply withholding anticoagulation. Which explanation BEST supports this plan?

A fall of more than 50% in platelets 5–10 days after starting heparin suggests heparin-induced thrombocytopenia (HIT). HIT is immune-mediated: antibodies activate platelets and cause new arterial and venous clots, so all heparin is stopped and a non-heparin anticoagulant is needed to prevent thrombosis.

Why the platelet drop points to HIT, not simple thrombocytopenia

A platelet count that falls from 240,000/mm³ on admission to 98,000/mm³ by day 7 of heparin represents a decline of roughly 59%. The timing and magnitude fit the classic window for heparin-induced thrombocytopenia (HIT), which typically appears 5–10 days after heparin exposure in a patient who has not previously received heparin. The drop is not explained by marrow suppression, clot consumption, or dilution; it is an immune-mediated adverse drug reaction.

In HIT, IgG antibodies form against complexes of platelet factor 4 (PF4) and heparin, and these antibody–PF4–heparin complexes bind platelet FcγRIIa receptors, causing intense platelet activation. Activated platelets release procoagulant microparticles, generate thrombin, and drive new arterial and venous thrombosis. This is why HIT is described as a prothrombotic state despite the low platelet count. The patient already has a pulmonary embolism, so the risk of additional clot formation is the central danger.

Watch out! The platelet count in HIT usually falls by 30–50% or more from baseline, and the median nadir is often 50,000–70,000/mm³. A count of 98,000/mm³ is therefore entirely consistent with HIT even though it is not severely low. Severe bleeding is uncommon; thrombosis is the dominant clinical threat.

Why stopping heparin alone is not enough

Simply discontinuing heparin leaves the patient without anticoagulation during a period of markedly increased thrombotic risk. The ASH 2018 guideline emphasizes that once HIT is suspected, all heparin must be stopped immediately, including heparin flushes and heparin-coated catheters, and a non-heparin anticoagulant must be started without waiting for laboratory confirmation. The reason is that the pathogenic antibodies remain capable of activating platelets for days after heparin is withdrawn, and the patient continues to generate thrombin.

The non-heparin options include direct thrombin inhibitors such as argatroban or bivalirudin, and factor Xa inhibitors such as danaparoid or fondaparinux. These agents do not cross-react with the HIT antibody and therefore interrupt the ongoing prothrombotic process. The physician’s decision to start a non-heparin anticoagulant rather than merely observe reflects this principle: the goal is not only to remove the trigger but also to suppress thrombin generation while the immune response resolves.

Why the other options fail

Option	Proposed mechanism	Why it is incorrect
1. Marrow suppression	Heparin directly suppresses platelet production	Heparin does not cause clinically significant marrow suppression. HIT is an immune reaction, not a direct toxic effect on megakaryocytes.
2. Clot consumption	Platelets are consumed by the pulmonary embolism	A localized PE does not typically consume enough platelets to drop the count by 59%. The timing on day 7 also fits an immune reaction better than acute consumption.
3. Dilution from IV fluids	Intravenous fluids lowered the platelet concentration	Dilutional thrombocytopenia is usually mild and occurs early with massive fluid resuscitation. It does not produce a progressive drop over 7 days in a stable ICU patient.
4. Antibody-mediated platelet activation	Heparin-dependent antibodies activate platelets and cause new clots	This is the correct explanation. It accounts for the timing, the degree of fall, and the need for a non-heparin anticoagulant.

Clinical application for the nursing licensure examinee

The 4Ts scoring system is the bedside tool used to estimate pretest probability of HIT. This patient would score high on Thrombocytopenia (fall greater than 50%), Timing (day 5–10 after heparin), Thrombosis (confirmed PE), and absence of oTher causes. A high 4Ts score triggers immediate heparin cessation and initiation of a non-heparin anticoagulant while laboratory testing proceeds.

Key point! HIT is a clinicopathologic diagnosis: treatment must begin on clinical suspicion, not after antibody test results return. The functional assay (serotonin release assay) and immunoassay (PF4–heparin ELISA) support the diagnosis, but delaying treatment while awaiting results risks new thrombosis. The nurse’s role includes verifying that all heparin sources are removed, documenting the platelet trend, and ensuring the non-heparin anticoagulant is administered without interruption ^[2][3][4].